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Abstract
Background: A fatty  acid (FA) is a carboxylic acid with a long aliphatic chain, which is either 
saturated or unsaturated. Recently, the role of FA and particularly omega-3 and -6 has 
emerged as cardiovascular risk factor in the literature. The aim of our study was to establish 
reference values for these FA and to compare them with data obtained in a population of acute 
myocardial infarction (AMI) patients.
Materials and methods: Hundred thirty  five healthy  subjects (59.38 ±  27.12 yo, 75 men) 
were selected as reference population. We also evaluated FA in thirty  three patients (55 ± 9 
yo, 23 men) admitted in the Emergency Department of our Institution for AMI. The fasting 
whole blood was drawn in vacutainer containing EDTA. Before analysis, samples were 
washed and transmethylated. We performed the quantification of different FA by gas 
chromatography associated with flame ionisation detector (GCFID).
Results: We obtained results in control healthy patients to be used as reference values. In the 
AMI group, levels of omega-6 were significantly higher (p<0.05) for C18:2n6 and C18:3n6 
than the reference population and omega-3 values were significantly lower (p<0.01) 
compared to reference value for C22:6n3. The omega-3 index was lower and the ratio 
omega-6/omega-3 was higher in AMI group compared to reference values.
Conclusions: We have established reference value for FA and have compared these values 
with the results obtained in AMI population. FA determination is a new tool we are able to use 
and to process in our laboratory which can help  the clinician to screen patients with the 
highest cardiovascular risks because of the implication of FA in the etiopathogeny of 
atherosclerosis.
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Introduction : 
A fatty acid (FA) is a carboxylic acid with a long aliphatic chain. This chain can either be 
saturated or unsaturated. Most naturally  occurring FA have a chain of 4 to 28 carbon atoms. 
FA are produced by hydrolysis of the ester linkages in a fat  or biological oil (both of which 
are triglycerides), with the removal of glycerol. There are many families of FA: “essential FA” 
with omega-3, omega-6, omega-7, omega-9, “saturated” FA (SFA) and “unsaturated” (cis and 
trans) FA. Table 1 shows the fatty  acids with their common name, the International Union of 
Pure and Applied Chemists (IUPAC) name and the formula (1). For many years, research has 
focused on the involvement of fatty  acids and their repercussions on the cardiovascular 
system.
The implication of FA, particularly, omega-3 and -6 in different diseases have been widely 
published in literature (2-9). SFA, abundantly  found in our diet, participate in the 
development of certain metabolic abnormalities such as insulin resistance or atherosclerosis 
(22, 23). However, all SFA have different metabolic effects. For example, palmitic acid 
(which consists of 50% palm oil versus a maximum of 17% for other oils such as peanut oil), 
unlike other SFA such as stearic acid, is a potent inhibitor of the intracellular pathway for 
insulin in some tissues such as skeletal muscle (22, 24). SFA are also considered as pro-
inflammatory agents because they  stimulate the inflammatory  response in different cell types, 
such as adipocytes, particularly during the postprandial phase (24, 25). Finally, this class of 
fatty acids probably  contributes to the development of atherosclerotic plaques because it 
causes increased plasma concentrations of LDL-cholesterol (24). All of this knowledge means 
that the current intake of SFA in western food, and in particular, palmitic acid, is a key player 
in the expansion of certain metabolic diseases such as type 2 diabetes, cardiovascular disease 
or metabolic syndrome (8, 26). Dietary  long-chain, polyunsaturated fatty acid (PUFA) also 
benefit the blood vessel wall by enhancing cell membrane fluidity and regulating membrane 
receptors (21).
Hundreds of epidemiological studies, either of mechanisms of action, or experimental in 
animals have shown that dietary  intake of omega-3 FA presented anti atherosclerotic potential 
(10-18). The role of FA in the atherosclerosis process was already discussed by Sinclain in 
1956 in the Lancet (19). 
Some authors have demonstrated that  the protective effect of omega-3 PUFAs in sudden 
cardiac death which was most often due to ventricular arrhythmia (5, 27). However, in 
patients with implantable cardioverter defibrillators and cardiac failure, no benefit of 
supplementation with omega-3 could be established (28). The erythrocyte fatty acid profile is 
modified; the omega-3 PUFA concentrations are elevated and predict the risk of ventricular 
arrhythmia. These results highlight an altered cardiac metabolism in patients with heart  failure 
and may have clinical implications for early identification of subjects at high risk (29). 
In general, prospective epidemiological studies have shown a relationship between intake of 
trans fatty  acids and increased morbidity  and mortality  from cardiovascular disease in Europe 
and North America (30, 31). The incomes of trans fatty acids compared to the intake of cis 
fatty acids, increases levels of LDL-cholesterol, triglycerides, lipoprotein Lp (a) and 
decreasing levels of HDL-cholesterol and the actual particle size of LDL-cholesterol. Each 
point may increase the risk of coronary heart disease (32). 
An important concept in the field of fatty acids is the balance omega-6/omega-3. An ideal 
relationship  for dietary intake would be 1:1 but it  is rather around the ratio of 15:1, linked to 
deficiency of omega-3 PUFA intakes. The increase in the proportion of omega-6 PUFA is 
considered as a risk factor for many diseases such as heart disease, inflammatory, 
autoimmune and various cancers (2). Freije compared the fatty acid composition of 
erythrocyte membranes in healthy patients with those of patients with coronary heart  disease 
in Bahrain (2). The results mainly  showed a low level of docosahexaenoic acid which 
increases the risk of coronary heart disease. Moreover, there was also an increased ratio of 
omega-6/omega-3. A omega-3 index decrease (which is the sum of the percentages of 
docosahexaenoic acid and eicosapentaenoic acid), was also observed in these patients (3).
The aim of our study was to establish reference values for these FA and to compare the results 
obtained with data observed in patients with acute myocardial infarction (AMI) seen the 
protector role of  PUFA particularly, omega-3, and the implication of SFA in the development 
of atherosclerosis (20).
Materials and methods
Hundred thirty five healthy subjects (59.38 ±  27.12 yo, 75 men) were selected as reference 
population (patient without cardiac antecedent or diabetes). We also evaluated FA in thirty 
three patients (55 ± 9 yo, 23 men) admitted in the Emergency Department of our Institution 
for AMI. All patients gave their informed consent.
Fasting whole blood samples were drawn in vacutainer tubes containing EDTA. One millilitre 
of whole blood was centrifuged at 3500 rpm for 5 min at 4° C. Plasma was carefully 
separated and the red blood cells (RBC) pellet was washed three times with equal volumes of 
standard saline. All the washings were carried out at 4°C. The white viscous material after 
each washing was carefully  removed to minimise contamination by  non-erythrocytic cells. 
The samples were finally stored at -20°C until analysed (personal data).
Before analysis, the samples were washed and an extraction was done.
Briefly, 0.3 ml packed RBCs were placed in a 5 ml clean glass vial with 100 µl of C28 
(Internal Standard). RBCs were then treated with 2 ml of methanolic-HCl 95%/5%. The vials 
were sealed and incubated at 80 °C for 2 h. After incubation the mixture was treated with 5 ml 
of hexane and centrifuged at 3500 rpm for 10 min at room temperature using a swinging rotor. 
The top  aqueous layer comprised mainly of methylated fatty acids. Hexane mixture was then 
carefully  collected in a separate vial. This step  was repeated three times and all extractions 
were pooled. The methylated-fatty acids hexane mixture was then completely  dried at 55°C 
under nitrogen. Methylated fatty acids were dissolved in 100 µl hexane and 1 µl was 
identified and quantified by gas chromatography with flame ionisation detector (GC/FID) 
performed on a Shimadzu GC2010, using a capillary column SP-2380 of 30 mm X 0.25 
mmX0.20 µm dimensions (Supelco). A FID was used with an oven temperature set at 250°C. 
The temperature of the injector was 250°C whereas the detector was set at 260°C.
The quantification of FA is realised according to the calibration curve that we have 
established with standards for all peaks that we must identify. 
First, we expressed the results in mg/L and after we chose to express results in percent (%) 
from the total of results. The sum of the FA found in a patient equals 100% and with a simple 
calculation we expressed them in % in relation to the sum of FA.
Results
Figure 1 shows the chromatographic profile of the different FA analysed.  For the reference 
values fro the Belgian population, we present the calculated values in the table 2. 
The table 3 presents the comparison of the results observed in AMI and in healthy  subjects. 
We obtained differences between AMI group and our healthy population.
In AMI, the levels of omega-6 were significantly higher (p<0.05) for C18:3n6. The level of 
omega-3 was lower in comparison with reference values but not significantly. We also 
calculated the omega-3 index and the ratio omega-6 / omega-3. The omega-3 index was 
significantly lower (p<0.0001) in AMI compared to the reference value and the omega-6 / 
omega-3 ratio was significantly  higher (p<0.005) in AMI than in reference patients.  The sum 
of SFA was also significantly  higher in AMI group  (p<0.05).We also noted a significantly 
difference (p<0.005) between both types of patients for C18:1n9. 
Discussion:
The incidence of cardiovascular disease is different between the countries and increases from 
Southern to the Northern countries (Europe) (33, 34).
Cardiovascular diseases are the first cause of mortality and morbidity in the developed 
countries. They are the world’s largest killers, claiming 17.1 million lives a year (35). This 
incidence has increased with time. One explanation is probably  found in changes of life style: 
aging, tobacco use, unhealthy diet, stress, physical inactivity  and harmful use of alcohol 
increase the risk of heart attacks and strokes (35). Atherosclerosis initiation and early 
progression is almost invariability a result of abnormal interactions between circulating 
oxidised lipids and blood vessel walls. Endothelial dysfunction has been linked to diverse 
vascular abnormalities like atherosclerosis. The first detectable stage in atherosclerosis is a 
slightly raised, fatty “streak” in the arterial wall. Among Western populations, these can be 
found in most individuals beginning as early  as the teenage years (21). In Northern of Europe, 
it is well known that people do not follow the Mediterranean diet, which has long been 
celebrated as the gold standard of healthy diet for its favourable impact on the prevention of 
chronic diseases, promotion of greater longevity and quality of life (36).
We have studied AMI patients because they are at risk of a second myocardial infarction due 
to their cardiovascular risk phenotype. Moreover, the implication of SFA and PUFA in the 
etiopathogeny of atherosclerosis is well known. We found thus very interesting to be able to 
make the quantification of these different FA to achieve on the dietary  prevention 
(supplementation in omega-3, decrease of intake of SFA…).
For the SFA, we observed a statistical increase between AMI and control subjects. These 
results are in accordance with Walrand at al.’s study (24), which explained that SFA was a key 
player in the expansion of cardiovascular disease. This class of fatty acids is most likely 
involved in the development of atherosclerosis probably due to the induced increasing of 
plasma concentrations of LDL-cholesterol. However, one of the limitations of our study  is 
without any doubt the age difference between both patient groups as well as daily  hygiene 
which we were able to define with our control group but not with the AMI group.
Our study also showed a statistically significant difference between the percentages of oleic 
acid (C18: 1n 9c) in the 2 groups. This increase in oleic acid has also been observed in the 
study of Harris and al.(4) who studied the lipid profile and erythrocytic plasma after 
myocardial infarction. It must be said that this fatty  acid is often considered beneficial as it 
benefits from the positive image of olive oil, containing 70% oleic acid, and no less 
favourable than the Mediterranean diet. However, a portion of beneficial effects in olive oil on 
endothelial functions, inflammation, platelet aggregation, and perhaps even on HDL 
cholesterol is the lipid fraction of the olive oil (37). 
In regards to trans fatty acids some statistically significant  difference (p<0.005) was observed 
between the 2 groups although many articles (32, 38) show the harmful effects related to the 
consumption of trans fatty  acids on the development of cardiovascular risk factors. Indeed, 
they  are proven to increase levels of LDL-cholesterol, triglycerides, lipoprotein Lp (a), and 
lower levels of HDL-cholesterol as well as particle size of LDL-cholesterol. It is for all these 
reasons that the political authorities try to regulate the possible content of trans fat in food.
In this study, we observed differences between the two studied groups in terms of 
docosahexaenoic acid (C22: 6 n 3), omega-6/omega-3 ratio and the omega-index, but also a 
significant difference for linoleic acid (C18: 2 n6c). These differences are consistent with both 
studies (3, 39), which highlighted the same differences. However in the Freije’s study, the 
percentage of C22: 6 n3 decreased from 2.81% to 0.41% and the ω3 index from 3.14% to 
0.64% in control subjects and AMI patients (2). These results were obtained in the kingdom 
of Bahrain and the authors believe that  these low values of C22: 6 n3 could be due to very 
low omega-3 fatty acids in fish inhabiting nearby waters (2). The attempts to corroborate the 
higher results were obtained. 
Conclusions
We have established reference values for FA implicated in different pathologies like 
cardiovascular diseases. This is a new tool we are able to use in our laboratory which can help 
clinicians to highlight and target patients with a higher cardiovascular risks. The clinicians 
could than supplement the patients with, for example, omega-3 to reduce the risk of 
developing cardiac diseases because the implication of FA in the etiopathogeny of 
atherosclerosis.
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Figure 1: The chromatographic profile of the different FA analysed.
Table 1: Fatty acids with their common name, the International Union of Pure and Applied 
Chemists (IUPAC) name and the formula.
Symbol Chemical structure Acid’s common name IUPAC name
Saturated fatty acid
C14:0 CH3(CH2)12COOH Myristic acid tétradécanoïque
C15:0 CH3(CH2)13COOH Pentadecanoic acid Pentadecanoic 
C16:0 CH3(CH2)14COOH Palmitic acid hexadecanoic
C17:0 CH3(CH2)15COOH Margaric acid heptadecanoic
C18:0 CH3(CH2)16COOH Stearic acid octadecanoic
C20:0 CH3(CH2)18COOH Arachidic acid eicosanoic
Unsatured fatty acid  ω-3
C18 : 3 ω-3 CH3(CH2CH=CH)3(CH2)7COOH α-linolenic acid cis,cis,cis-9,12,15-
octadécatrienoic
C20 : 5 ω-3 CH3CH2(CH=CHCH2)4CH=CH(C
H2)3COOH
Eicosapentaenoic acid cis,cis,cis,cis,cis-5,
8 , 1 1 , 1 4 , 1 7 -
eicosapentaenoic
C22 : 5 ω-3 CH3CH2CH=CH(CH2)2CH=CHC
H2(CH=CH (CH2)2)3COOH
Docosapentaenoic acid cis,cis,cis,cis,cis-4,
8 , 1 2 , 1 5 , 1 9 -
docosapentaenoic





Unsatured fatty acid ω-6
C18 : 2 ω-6 CH3(CH2)4CH=CHCH2CH=CH(C
H2)7COOH
Linoleic acid c i s , c i s - 9 , 1 2 -
octadecadienoic










C20 : 4 ω-6 CH3(CH2)4(CH=CHCH2)3CH=CH(
CH2)3COOH
Arachidonic acid cis,cis,cis,cis-5,8,11
, 1 4 -
eicosatetraenoic
Others unsatured fatty acid
C16 : 1 ω-7 CH3(CH2)5CH=CH(CH2)7COOH Palmitoleic acid cis-9-hexadécénoic
C18 : 1 ω-9 CH3(CH2)7CH=CH(CH2)7COOH Oléic acid cis-9-octadécénoic
C20 : 1 ω-9 CH3(CH2)7CH=CH(CH2)9COOH Gondoic acid cis-9-eicosénoic
Trans unsatured fatty acid  
C18 : 1 ω-9 CH3(CH2)7CH=CH(CH2)7COOH Elaidic acid t r a n s - 9 -
octadecenoic
C18 : 2 ω-6 CH3(CH2)4CH=CHCH=CH(CH2)8
COOH
Linolelaidic acid t rans ,c i s -10 ,12-
octadecadienoic
Table 2: Reference values for the Belgian population (n=135).
Table 3: Comparison between AMI and reference group for FA (FA in %).
